William Whitson, MD
Ophthalmology · Indianapolis, INNPI 1912935313
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Beaver-visitec International, Inc. at 35.4% of the total. Reporting peaked in 2022 at $6,270 and has fallen 73.2% since, to $1,679 in 2025. Among ophthalmology clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 161 payments — averaging $94.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Beaver-visitec International, Inc.$5K
- Rxsight Inc$3K
- Tarsus Pharmaceuticals, Inc.$1K
- Glaukos Corporation$1K
- AbbVie$716
- Lensar, Inc.$704
- plus $3K from 21 others
Across 16 payments — averaging $6375.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$70K
- Beaver-visitec International, Inc.$19K
- Aerie Pharmaceuticals, Inc.$10K
- Tarsus Pharmaceuticals, Inc.$2K
What the payments were for
- Consulting fees$7,63050%
- Speaking & faculty fees$260%
- Travel & lodging$1581%
- Food & beverage$7,24748%
- Gifts$1211%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Beaver-visitec International, Inc. | 1 | $5,380 |
| Rxsight Inc | 13 | $2,962 |
| Tarsus Pharmaceuticals, Inc. | 14 | $1,130 |
| Glaukos Corporation | 18 | $1,109 |
| AbbVie(2 entities) | 18 | $716 |
| Lensar, Inc. | 6 | $704 |
| Johnson & Johnson Surgical Vision, Inc. | 15 | $514 |
| Biotissue Holdings Inc. | 8 | $492 |
| Mallinckrodt Hospital Products Inc. | 5 | $343 |
| Ocular Therapeutix, Inc. | 5 | $234 |
| Sun Pharmaceutical Industries Inc. | 11 | $226 |
| Harrow Eye, LLC | 6 | $211 |
| Novartis | 8 | $209 |
| Dompe US, Inc. | 4 | $193 |
| Bausch & Lomb Americas Inc. | 4 | $181 |
| Oyster Point Pharma, Inc. | 7 | $146 |
| Amgen | 1 | $121 |
| Carl Zeiss Meditec USA, Inc. | 3 | $67 |
| NEW World Medical,inc. | 3 | $53 |
| Omeros Corporation | 3 | $48 |
| Alcon | 2 | $34 |
| Thea Pharma Inc. | 1 | $23 |
| Tearlab Corp | 1 | $23 |
| Rayner Intraocular Lenses Limited | 1 | $20 |
| Eyevance Pharmaceuticals LLC | 1 | $15 |
| Kala Pharmaceuticals, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$2,755
- iStent infinite Trabecular Micro-Bypass System Model iS3$507
- XDEMVY$503
- LENSAR LASER SYSTEM$413
- Prokera$376
- AmnioGraft$376
- AmnioGuard$376
- ACTHAR$268
- iS3-iStent infiniteTrabecular Micro-Bypass System Model iS3$173
- iDoseTR$171
- iDose$146
- XEN GLAUCOMA TREATMENT SYSTEM$137
- DEXTENZA$136
- RESTASIS$125
- DURYSTA$124
- Tecnis Multifocal Family of 1-piece IOLS$122
- Oxervate$121
- PAVBLU$121
- MIEBO$113
- XIIDRA$113
How this compares
$15,181 in reported general payments places this provider in the 90th percentile of 266 ophthalmology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XdemvyLotilaner | 27 | $51,273 |
| RestasisCyclosporine | 41 | $36,256 |
| Prednisolone Acetate | 524 | $18,553 |
| RocklatanNetarsudil Mesylat/Latanoprost | 28 | $12,237 |
| MieboPerfluorohexyloctane/Pf | 16 | $12,234 |
| Ketorolac Tromethamine | 352 | $6,878 |
| Loteprednol Etabonate | 26 | $5,282 |
| CombiganBrimonidine Tartrate/Timolol | 14 | $4,848 |
| Ofloxacin | 287 | $3,088 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 18 | $2,236 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 24 | $1,544 |
| Latanoprost | 94 | $1,153 |
| Dorzolamide Hcl | 24 | $540 |
| Timolol Maleate | 53 | $430 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 24 | $296 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Tarsus Pharmaceuticals, Inc.Xdemvy | $1,130 | $51,27327 claims |
| AbbVieRestasis, Combigan | $716 | $41,10455 claims |
| Bausch & Lomb Americas Inc.Miebo | $181 | $12,23416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 266 ophthalmology providers in Indiana.
Other ophthalmology in Indianapolis
- Kevin WaltzIndianapolis$199K
- Janet HummerIndianapolis$96K
- Francis PriceIndianapolis$67K
- Michael OrrIndianapolis$26K
- Matthew FengIndianapolis$22K
- John LindIndianapolis$20K
- Shaohui LiuIndianapolis$19K
- John LatonaIndianapolis$18K
- Thierry WilbrandtIndianapolis$13K
- Anthony LombardoIndianapolis$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.